|
Table 2: Receptors for activation and inhibition of NK cells. |
||
|
Activation receptors |
Linking |
Reference |
|
NKG2C NKG2D NKG2E KIR2-DS1 KIR2-DS2 KIR3-D NKp30 NKp44 NKp46 NKp80 CD16 CD94 DNAM-1 |
HLA-E MIC (a and b) and ULBP (1-6) HLA-E HLA-C2 (lysine in position 80) HLA-C2 with viral peptide HLA-F B7-H6, HCMV-pp65, BAG6, heparan sulfate MLL5, viral hemagglutinin, PCNA, PDGF-DD Complement factor P, viral hemagglutinin, heparan sulfate AICL IgG antibody complex section HLA-E CD155 and CD112 |
34, 35 34-36 34, 35 34, 37 34, 37 34, 35 22, 34 22, 34 22, 34 38 34, 35 34, 35 34, 38 |
|
Inhibitory receptors |
||
|
KIR2DL1 KIR2DL2/3 KIR3DL1 KIR3DL2 NKG2A NKRP1A KLRG1 PD1 |
HLA-C2 (lysine in position 80) HLA-C1 (asparagine in position 80) and HLA-C2 (lysine in position 80) HLA-A, HLA-Bw4 HLA-Aw3, HLA-Aw11 Inhibitory peptide in HLA-E LLT1 Cadherins PDL1-L2 |
34 34 34 34 34 34 34 38 |
|
AICL = activating inducing ligand. BAG6 = scythe protein. HCMV = human cytomegalovirus. HLA = human leukocyte antigen. LLT1 = lectin-like transcript. MIC = class I chain-related protein. MLL5 = mixed lineage leukemia 5. PCNA= proliferating cell nuclear antigen. PDGF-DD = platelet-derived growth factor-DD. PDL1 = programmed death-ligand 1. ULBP= UL16-binding proteins. |
||